Sarepta Therapeutics Statistics Share Statistics Sarepta Therapeutics has 97.71M
shares outstanding. The number of shares has increased by 3.05%
in one year.
Shares Outstanding 97.71M Shares Change (YoY) 3.05% Shares Change (QoQ) 1.28% Owned by Institutions (%) 89.36% Shares Floating 87.65M Failed to Deliver (FTD) Shares 1,929 FTD / Avg. Volume 0.02%
Short Selling Information The latest short interest is 20.28M, so 19.37% of the outstanding
shares have been sold short.
Short Interest 20.28M Short % of Shares Out 19.37% Short % of Float 22.46% Short Ratio (days to cover) 3.59
Valuation Ratios The PE ratio is 49.14 and the forward
PE ratio is 7.38.
Sarepta Therapeutics's PEG ratio is
-0.35.
PE Ratio 49.14 Forward PE 7.38 PS Ratio 6.08 Forward PS 1.1 PB Ratio 7.57 P/FCF Ratio -33.73 PEG Ratio -0.35
Financial Ratio History Enterprise Valuation Sarepta Therapeutics has an Enterprise Value (EV) of 11.8B.
EV / Sales 6.2 EV / EBITDA 35.43 EV / EBIT -57.34 EV / FCF -34.43
Financial Position The company has a current ratio of 4.2,
with a Debt / Equity ratio of 0.88.
Current Ratio 4.2 Quick Ratio 3.18 Debt / Equity 0.88 Debt / EBITDA 4.03 Debt / FCF -3.92 Interest Coverage 11.86
Financial Efficiency Return on Equity is 15.4% and Return on Invested Capital is 6.06%.
Return on Equity 15.4% Return on Assets 5.94% Return on Invested Capital 6.06% Revenue Per Employee $1.39M Profits Per Employee $171.46K Employee Count 1,372 Asset Turnover 0.48 Inventory Turnover 0.43
Taxes Income Tax 25.54M Effective Tax Rate 9.79%
Stock Price Statistics The stock price has increased by -85.26% in the
last 52 weeks. The beta is 0.49, so Sarepta Therapeutics's
price volatility has been higher than the market average.
Beta 0.49 52-Week Price Change -85.26% 50-Day Moving Average 17.56 200-Day Moving Average 60.17 Relative Strength Index (RSI) 50.9 Average Volume (20 Days) 12,049,171
Income Statement In the last 12 months, Sarepta Therapeutics had revenue of 1.9B
and earned 235.24M
in profits. Earnings per share was 2.34.
Revenue 1.9B Gross Profit 1.58B Operating Income 218.08M Net Income 235.24M EBITDA 333.06M EBIT 279.17M Earnings Per Share (EPS) 2.34
Full Income Statement Balance Sheet The company has 1.1B in cash and 1.34B in
debt, giving a net cash position of -240.06M.
Cash & Cash Equivalents 1.1B Total Debt 1.34B Net Cash -240.06M Retained Earnings -4.21B Total Assets 3.68B Working Capital 1.74B
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -205.79M
and capital expenditures -136.96M, giving a free cash flow of -342.74M.
Operating Cash Flow -205.79M Capital Expenditures -136.96M Free Cash Flow -342.74M FCF Per Share -3.6
Full Cash Flow Statement Margins Gross margin is 83.22%, with operating and profit margins of 11.47% and 12.37%.
Gross Margin 83.22% Operating Margin 11.47% Pretax Margin 13.71% Profit Margin 12.37% EBITDA Margin 17.51% EBIT Margin 11.47% FCF Margin -18.02%
Dividends & Yields SRPT does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield 2.03% FCF Yield -2.96%
Dividend Details Analyst Forecast The average price target for SRPT is $19,
which is 3.5% higher than the current price. The consensus rating is "Hold".
Price Target $19 Price Target Difference 3.5% Analyst Consensus Hold Analyst Count 28
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number 29.91 Graham Upside 62.91%
Stock Splits The last stock split was on Jul 12, 2012. It was a
backward
split with a ratio of 1:6.
Last Split Date Jul 12, 2012 Split Type backward Split Ratio 1:6
Scores Altman Z-Score 0.01 Piotroski F-Score 1
